16907-09-8

Basic information

• Product Name: 1-(4-Methoxyphenyl)-1H-pyrazol-5-amine
• Synonyms: 1-(4-Methoxyphenyl)-1H-pyrazol-5-amine;2-(4-Methoxyphenyl)-2H-pyrazol-3-ylamine
• CAS NO: 16907-09-8
• Molecular Formula: C₁₀H₁₁N₃O
• Molecular Weight: 189.21384
• Mol File: 16907-09-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-Methoxyphenyl)-1H-pyrazol-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Methoxyphenyl)-1H-pyrazol-5-amine(16907-09-8)
• EPA Substance Registry System: 1-(4-Methoxyphenyl)-1H-pyrazol-5-amine(16907-09-8)

Safety Data

• Hazardous Substances Data: 16907-09-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Methoxyphenyl)-1H-pyrazol-5-amine is used as a building block for the synthesis of various drugs and organic compounds. Its unique structure allows it to be a valuable component in the development of new pharmaceuticals, potentially leading to the creation of novel medications with improved efficacy and reduced side effects.
Used in Chemical Industry:
In the chemical industry, 1-(4-Methoxyphenyl)-1H-pyrazol-5-amine is used as a key intermediate in the production of a wide range of organic compounds. Its versatility in chemical reactions makes it a valuable asset for the synthesis of various chemical products, including dyes, pigments, and other specialty chemicals.
Potential Applications:
While the provided materials do not explicitly mention specific applications, the potential biological and pharmacological activities of 1-(4-Methoxyphenyl)-1H-pyrazol-5-amine suggest that it may be used in the development of new therapeutic agents. Further research is necessary to fully understand its potential applications in various fields, such as medicine, agriculture, and materials science.

Upstream product

• 1820-80-0 3-aminopyrazole 
• 696-62-8 para-iodoanisole 
• 3471-32-7 4-Methoxyphenylhydrazine 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 
• 15001-13-5 ethyl 5-amino-1-(4-methoxy)phenyl-1H-pyrazole-4-carboxylate 

Downstream Products

• 1200440-28-3 2-bromo-N-[2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]-acetamide 
• 1200439-60-6 2-[1-(2,5-dimethyl-phenyl)-1H-tetrazol-5-ylsulfanyl]-N-[2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]-acetamide 
• 14679-02-8 4-acetylamino-N-[2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]-benzenesulfonamide 

Relevant articles and documents

The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition

In this study, a series of sulfonamide compounds was designed and synthesized through the systematic optimization of the antibacterial agent sulfaphenazole for the treatment of Mycobacterium tuberculosis (M. tuberculosis). Preliminary results indicate that the 4-aminobenzenesulfonamide moiety plays a key role in maintaining antimycobacterial activity. Compounds 10c, 10d, 10f and 10i through the optimization on phenyl ring at the R2 site on the pyrazole displayed promising antimycobacterial activity paired with low cytotoxicity. In particular, compound 10d displayed good activity (MIC = 5.69 μg/mL) with low inhibition of CYP 2C9 (IC50 > 10 μM), consequently low potential risk of drug-drug interaction. These promising results provide new insight into the combination regimen using sulfonamide as one component for the treatment of M. tuberculosis.

Copper(I)/Copper(II)-Assisted Tandem Catalysis: The Case Study of Ullmann/Chan-Evans-Lam N1,N3-Diarylation of 3-Aminopyrazole

Unprecedented CuI/CuII-assisted tandem catalysis allowing an Ullmann/Chan-Evans-Lam sequence was achieved. This three-component, one-pot reaction triggered by a change in the oxidation state of the metal leads to the selective N1,N3-diarylation of 3-aminopyrazole. This new method should be a valuable tool for small-molecule drug discovery that requires suitable regio- and/or chemoselective strategies for the N-arylation of nitrogen-containing heterocycles. Tandem power: The first assisted tandem copper-catalyzed process, triggered by a change in the oxidation state of the metal, is developed to allow a one-pot Ullman/Chan-Evans-Lam sequence leading to the selective N1,N3-diarylation of 3-aminopyrazole.

NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine alpha7 receptor.

PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.

TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R1, R2 and R3 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.

PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS

Disclosed are compounds having the formula (I): wherein Z, n, R1, R1A, R3, R4, and R5 are as defined herein, and methods of making and using the same.

TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R1, R2 and R3 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.